Antiangiogenic therapies: Going beyond their limits

Cancer Discovery

Volumn 4, Issue 1, 2014, Pages 31-41

  Moserle, Lidia ^a   Jiménez Valerio, Gabriela ^a   Casanovas, Oriol ^a  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ALPHA INTERFERON; ALPHA SMOOTH MUSCLE ACTIN; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; BETA CATENIN; BEVACIZUMAB; BIOLOGICAL MARKER; BRIVANIB; DOCETAXEL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; NEUROPILIN 1; PAZOPANIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID; SORAFENIB; STROMAL CELL DERIVED FACTOR 1; SUNITINIB; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VON HIPPEL LINDAU PROTEIN; VON WILLEBRAND FACTOR;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STEM CELL; CIRCULATING TUMOR CELL; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; FIBROBLAST; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; LIGAND BINDING; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; NEOPLASM; PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; REVIEW; TISSUE OXYGENATION; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84891893710     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.cd-13-0199     Document Type: Review

References (120)

1. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005;69(Suppl 3):4-10.
2. Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011;8:210-21.
3. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
4. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szc-zylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-11.
5. Gerhardt H, Semb H. Pericytes: gatekeepers in tumour cell metastasis? J Mol Med 2008;86:135-44.
6. Xian X, Hakansson J, Stahlberg A, Lindblom P, Betsholtz C, Ger-hardt H, et al. Pericytes limit tumor cell metastasis. J Clin Invest 2006;116:642-51.
7. Franco M, Roswall P, Cortez E, Hanahan D, Pietras K. Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. Blood 2011;118:2906-17.
8. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Ben-efi ts of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-95.
9. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005;23:939-52.
10. Saharinen P, Alitalo K. Double target for tumor mass destruction. J Clin Invest 2003;111:1277-80.
11. Thompson Coon JS, Liu Z, Hoyle M, Rogers G, Green C, Moxham T, et al. Sunitinib and bevacizumab for fi rst-line treatment of meta-static renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness. Br J Cancer 2009;101:238-43.
12. Rini BI. Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. Cancer 2009;115:2306-12.
13. Bukowski RM. Third generation tyrosine kinase inhibitors and their development in advanced renal cell carcinoma. Front Oncol 2012; 2: 13.
14. Liebler DC, Guengerich FP. Elucidating mechanisms of drug-induced toxicity. Nat Rev Drug Discov 2005;4:410-20.
15. Hasinoff BB, Patel D, O'Hara KA. Mechanisms of myocyte cyto-toxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib. Mol Pharmacol 2008;74:1722-8.
16. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24.
17. Bhojani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, Hutterer G, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008;53:917-30.
18. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, et al. Bevacizumab in combination with fl uorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23:3502-8.
19. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7: 987-9.
20. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
21. Willett CG, Boucher Y, Di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specifi c antibody bevaci-zumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-7.
22. Huber PE, Bischof M, Jenne J, Heiland S, Peschke P, Saffrich R, et al. Trimodal cancer treatment: benefi cial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res 2005;65: 3643-55.
23. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64:3731-6.
24. Batchelor TT, Sorensen AG, Di Tomaso E, Zhang WT, Duda DG, Cohen KS, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95.
25. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004;165:35-52.
26. Nakamura K, Taguchi E, Miura T, Yamamoto A, Takahashi K, Bichat F, et al. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res 2006;66:9134-42.
27. Nakahara T, Norberg SM, Shalinsky DR, Hu-Lowe DD, McDonald DM. Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res 2006;66:1434-45.
28. Kan Z, Kobayashi S, Phongkitkarun S, Charnsangavej C. Functional CT quantifi cation of tumor perfusion after transhepatic arterial embolization in a rat model. Radiology 2005;237:144-50.
29. Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 2012;21:82-91.
30. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006;290:H560-H576.
31. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
32. Weissleder R. Scaling down imaging: molecular mapping of cancer in mice. Nat Rev Cancer 2002;2:11-8.
33. Franco M, Man S, Chen L, Emmenegger U, Shaked Y, Cheung AM, et al. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res 2006;66: 3639-48.
34. Dings RP, Loren M, Heun H, McNiel E, Griffioen AW, Mayo KH, et al. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 2007;13:3395-402.
35. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404-7.
36. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.
37. Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009;10:992-1000.
38. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008;8:579-91.
39. Kindler HL. Pancreatic cancer: an update. Curr Oncol Rep 2007;9:170-6.
40. Kerbel RS. Therapeutic implications of intrinsic or induced ang-iogenic growth factor redundancy in tumors revealed. Cancer Cell 2005;8:269-71.
41. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438:932-6.
42. Kerbel RS. Molecular and physiologic mechanisms of drug resistance in cancer: an overview. Cancer Metastasis Rev 2001;20:1-2.
43. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309.
44. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6:392-401.
45. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related infl am-mation. Nature 2008;454:436-44.
46. Azam F, Mehta S, Harris AL. Mechanisms of resistance to antiang-iogenesis therapy. Eur J Cancer 2010;46:1323-32.
47. Rapisarda A, Melillo G. Role of the hypoxic tumor microenviron-ment in the resistance to anti-angiogenic therapies. Drug Resist Updat 2009;12:74-80.
48. Spannuth WA, Sood AK, Coleman RL. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol 2008; 5: 194-204.
49. Oberg K, Casanovas O, Castano JP, Chung D, Delle Fave G, Denefle P, et al. Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches. Clin Cancer Res 2013;19:2842-9.
50. Jimenez-Valerio G, Casanovas O. Molecular pathways and mechanisms of resistance to antiangiogenics. In:Galceran JC, editor. Integral atlas of renal cancer [in Spanish]. Madrid, Spain: You and Us; 2012. p. 75-81.
51. Allen E, Walters IB, Hanahan D. Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin Cancer Res 2011;17:5299-310.
52. Chou T, Finn RS. Brivanib: a review of development. Future Oncol 2012;8:1083-90.
53. Diaz-Padilla I, Siu LL. Brivanib alaninate for cancer. Expert Opin Investig Drugs 2011;20:577-86.
54. Jia Z, Zhang J, Wei D, Wang L, Yuan P, Le X, et al. Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mith-ramycin A. Cancer Res 2007;67:4878-85.
55. Teule A, Casanovas O. Relevance of angiogenesis in neuroendocrine tumors. Target Oncol 2012;7:93-8.
56. Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A 2012; 109: 2784-9.
57. Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B, et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in infl ammatory breast cancer. Clin Cancer Res 2010;16:45-55.
58. Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, Kerbel RS. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 2007;67:3560-4.
59. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006;66:7843-8.
60. Folkins C, Shaked Y, Man S, Tang T, Lee CR, Zhu Z, et al. Glioma tumor stem-like cells promote tumor angiogenesis and vasculo-genesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res 2009;69:7243-51.
61. Korkaya H, Paulson A, Charafe-Jauffret E, Ginestier C, Brown M, Dutcher J, et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol 2009;7:e1000121.
62. Ribatti D. Cancer stem cells and tumor angiogenesis. Cancer Lett 2012;321:13-7.
63. Moserle L, Ghisi M, Amadori A, Indraccolo S. Side population and cancer stem cells: therapeutic implications. Cancer Lett 2010;288: 1-9.
64. Madsen CD, Sahai E. Cancer dissemination-lessons from leukocytes. Dev Cell 2010;19:13-26.
65. Jain RK, Tong RT, Munn LL. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 2007;67:2729-35.
66. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2: 563-72.
67. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-31.
68. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-9.
69. Demir R, Naschberger L, Demir I, Melling N, Dimmler A, Papa-dopoulus T, et al. Hypoxia generates a more invasive phenotype of tumour cells: an in vivo experimental setup based on the chorioal-lantoic membrane. Pathol Oncol Res 2009;15:417-22.
70. Lu X, Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 2010;16:5928-35.
71. Lu KV, Chang JP, Parachoniak C A, Pandika MM, Aghi MK, Meyronet D, et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 2012; 22: 21-35.
72. Sennino B, Ishiguro-Oonuma T, Wei Y, Naylor RM, Williamson CW, Bhagwandin V, et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2012;2:270-87.
73. Shojaei F, Simmons BH, Lee JH, Lappin PB, Christensen JG. HGF/ c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis. Cancer Lett 2012;320:48-55.
74. Miles D, Harbeck N, Escudier B, Hurwitz H, Saltz L, Van Cutsem E, et al. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol 2010;29:83-8.
75. Potemski P. Is the postprogression survival time really not shortened in the bevacizumab-containing arms of phase III clinical trials? J Clin Oncol 2011;29:e384-5.
76. de Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 2012;13:1225-33.
77. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Lopa SH, et al. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J Clin Oncol 2013;31:359-64.
78. Bautch VL. Endothelial cells form a phalanx to block tumor metastasis. Cell 2009;136:810-2.
79. Mazzone M, Dettori D, Leite de Oliveira R, Loges S, Schmidt T, Jonckx B, et al. Heterozygous defi ciency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009;136:839-51.
80. Maione F, Capano S, Regano D, Zentilin L, Giacca M, Casanovas O, et al. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. J Clin Invest 2012;122:1832-48.
81. Maione F, Molla F, Meda C, Latini R, Zentilin L, Giacca M, et al. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J Clin Invest 2009;119:3356-72.
82. Subarsky P, Hill RP. Graded hypoxia modulates the invasive potential of HT1080 fi brosarcoma and MDA MB231 carcinoma cells. Clin Exp Metastasis 2008;25:253-64.
83. Faris JE, Michaelson MD. Targeted therapies: sunitinib versus inter-feron-alpha in metastatic RCC. Nat Rev Clin Oncol 2009;7:7-8.
84. Hotte SJ, Bjarnason GA, Heng DY, Jewett MA, Kapoor A, Kollmanns-berger C, et al. Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma. Curr Oncol 2011; 18 (Suppl 2): S11-S19.
85. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib effi cacy and future clinical development. Nat Rev Drug Discov 2007;6:734-45.
86. Rosner I, Bratslavsky G, Pinto PA, Linehan WM. The clinical implications of the genetics of renal cell carcinoma. Urol Oncol 2009;27:131-6.
87. Yoong KF, Afford SC, Randhawa S, Hubscher SG, Adams DH. Fas/ Fas ligand interaction in human colorectal hepatic metastases: a mechanism of hepatocyte destruction to facilitate local tumor invasion. Am J Pathol 1999;154:693-703.
88. Jin K, Lan H, Cao F, Han N, Xu Z, Li G, et al. Differential response to EGFR- and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases. Int J Oncol 2012;41:583-8.
89. Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, et al. Hypertension as a biomarker of effi cacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011;103:763-73.
90. Franco M, Paez-Ribes M, Cortez E, Casanovas O, Pietras K. Use of a mouse model of pancreatic neuroendocrine tumors to fi nd pericyte biomarkers of resistance to anti-angiogenic therapy. Horm Metab Res 2011;43:884-9.
91. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6:24-37.
92. Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Jung S, et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 2006;124:175-89.
93. Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegue E, et al. HIF1al-pha induces the recruitment of bone marrow-derived vascular mod-ulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008;13:206-20.
94. Maru DM, Venook AP, Ellis LM. Predictive biomarkers for bevacizu-mab: are we there yet? Clin Cancer Res 2013;19:2824-7.
95. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273-86.
96. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:2544-55.
97. Loges S, Schmidt T, Tjwa M, van Geyte K, Lievens D, Lutgens E, et al. Malignant cells fuel tumor growth by educating infi ltrating leukocytes to produce the mitogen Gas6. Blood 2010;115:2264-73.
98. Moserle L, Casanovas O. Anti-angiogenesis and metastasis: a tumour and stromal cell alliance. J Intern Med 2012;273:128-37.
99. Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, et al. A phase II trial of erlotinib in combination with bevaci-zumab in patients with metastatic breast cancer. Clin Cancer Res 2008;14:7878-83.
100. Ebos JM, Lee CR, Kerbel RS. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 2009;15:5020-5.
101. De Palma M, Lewis CE. Cancer: macrophages limit chemotherapy. Nature 2011;472:303-4.
102. Bronte V, Apolloni E, Cabrelle A, Ronca R, Serafini P, Zamboni P, et al. Identifi cation of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 2000;96:3838-46.
103. Jurgensmeier JM, Schmoll HJ, Robertson JD, Brooks L, Taboada M, Morgan SR, et al. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevaci-zumab and chemotherapy. Br J Cancer 2013;108:1316-23.
104. Lambrechts D, Claes B, Delmar P, Reumers J, Mazzone M, Yesilyurt BT, et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol 2012;13:724-33.
105. Bielenberg DR, Pettaway CA, Takashima S, Klagsbrun M. Neuropi-lins in neoplasms: expression, regulation, and function. Exp Cell Res 2006;312:584-93.
106. Rafii S, Lyden D, Benezra R, Hattori K, Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2002;2:826-35.
107. Ronzoni M, Manzoni M, Mariucci S, Loupakis F, Brugnatelli S, Bencardino K, et al. Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to beva-cizumab-based fi rst-line treatment in advanced colorectal cancer patients. Ann Oncol 2010;21:2382-9.
108. Le QT, Denko NC, Giaccia AJ. Hypoxic gene expression and metastasis. Cancer Metastasis Rev 2004;23:293-310.
109. Landskroner-Eiger S, Moneke I, Sessa WC. miRNAs as modulators of angiogenesis. Cold Spring Harb Perspect Med 2013;3:a006643.
110. Willett CG, Kozin SV, Duda DG, Di Tomaso E, Kozak KR, Boucher Y, et al. Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice. Semin Oncol 2006;33:S35-40.
111. Favaro E, Nardo G, Persano L, Masiero M, Moserle L, Zamarchi R, et al. Hypoxia inducible factor-1alpha inactivation unveils a link between tumor cell metabolism and hypoxia-induced cell death. Am J Pathol 2008;173:1186-201.
112. Plathow C, Weber WA. Tumor cell metabolism imaging. J Nucl Med 2008;49(Suppl 2):43S-63S.
113. Nardo G, Favaro E, Curtarello M, Moserle L, Zulato E, Persano L, et al. Glycolytic phenotype and AMP kinase modify the pathologic response of tumor xenografts to VEGF neutralization. Cancer Res 2011;71:4214-25.
114. Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen HY, et al. Autophagy suppresses tumorigenesis through elimination of p62. Cell 2009;137:1062-75.
115. Mathew R, White E. Autophagy in tumorigenesis and energy metabolism: friend by day, foe by night. Curr Opin Genet Dev 2011;21:113-9.
116. Zhang YW, Staal B, Essenburg C, Lewis S, Kaufman D, Vande Woude GF. Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR. Mol Cancer Ther 2013;12:1429-41.
117. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-91.
118. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007;13:7053-8.
119. Amadori A, Rossi E, Zamarchi R, Carli P, Pastorelli D, Jirillo A. Circulating and disseminated tumor cells in the clinical management of breast cancer patients: unanswered questions. Oncology 2009; 76: 375-386.
120. Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007;109:2257-67.